CurrentCentenePolicy CP PHAR.216

Factor VIII–von Willebrand Factor Complex and von Willebrand Factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Clinical coverage and prior authorization criteria for use of Alphanate, Humate-P, Wilate (plasma-derived FVIII-vWF complexes) and Vonvendi (recombinant vWF) for Hemophilia A and von Willebrand disease across Centene lines of business (Commercial, HIM, Medicaid).

Policy Summary

PayerCentene

PolicyFactor VIII–von Willebrand Factor Complex and von Willebrand Factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Policy CodePolicy CP PHAR.216

Change TypeAnnual revisions and clarifications (2021–2025)

Effective DateMay 1, 2016

Next Review Date

Key ActionProvider must obtain prior authorization and submit supporting documentation (office notes, labs, weight, bleed history) demonstrating that the member meets all applicable initial or continued therapy criteria.

SourceLink

POLICY UPDATE CHANGES

Revised desmopressin acetate trial requirement to apply only for age ≥ 2 years.

Added requirement for documentation of member's body weight for dosing calculations.

Clarified that documentation of FVIII activity level and bleed history requirement applies only to new starts of routine prophylactic therapy (Wilate).

Updated authorization durations for prophylaxis and surgical/acute bleeding across Medicaid/HIM/Commercial lines (various changes culminating in 1Q 2025 updates).

Removed 'life-threatening' wording from serious bleed definition to avoid confusion; updated sites of serious bleeds per WFH guidelines.

4Products covered by this policy (Alphanate, Humate-P, Wilate, Vonvendi)

≥2

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Age threshold for desmopressin trial requirement (years)

RequiredMember weight required for dosing calculations

3-12Typical approval durations depending on indication and line of business

Medical Necessity Criteria

Initial Approval — Congenital Hemophilia A (FVIII deficiency)

Alphanate, Humate-P, or Wilate are medically necessary when ALL of the following are met:

ALL of the following

Diagnosis of congenital hemophilia A (factor VIII deficiency).
Request is for Alphanate, Humate-P, or Wilate.
Prescribed by or in consultation with a hematologist.
Indication type (at least one required)
- Control or prevention of bleeding episodes.
- Perioperative management (Alphanate only).
- Routine prophylaxis to reduce frequency of bleeding episodes (Wilate only).
If request is for routine prophylaxis (Wilate only), new start must meet one of:
- Member has severe hemophilia (FVIII level < 1%).
- Member has experienced at least one serious spontaneous bleed (see Appendix D for definition/sites).
Desmopressin (DDAVP) requirement for age ≥2 years when applicable
- For age ≥ 2 years and FVIII coagulant activity levels ≤ 5%, failure of desmopressin acetate is required prior to product, unless contraindicated, clinically significant adverse effects occur, or appropriate formulation is unavailable.
Dose does not exceed the FDA-approved maximum recommended dose for the relevant indication.

Initial Approval — Von Willebrand Disease (VWD)

Humate-P, Wilate, or Vonvendi are medically necessary for VWD when ALL of the following are met:

ALL of the following

Diagnosis of von Willebrand disease (VWD).
Prescribed by or in consultation with a hematologist.
For Vonvendi requests: patient age ≥ 18 years (unless other product-specific criteria apply).
Desmopressin (DDAVP) trial requirement
- For applicable VWD patients (type 1 or 2 except 2B) age ≥ 2 years and FVIII activity thresholds, failure of desmopressin acetate is required unless contraindicated, adverse effects occur, or formulation unavailable.
Permitted uses (one required)

Diagnoses/Indications Not Authorized

Coverage is not authorized for:

ANY of the following

Non-FDA-approved indications that are not addressed in this policy unless supported by sufficient documentation per off-label use policies (CP.CPA.09, HIM.PA.154, CP.PMN.53).

Coding and Billing Guidance

HCPCS / J-codes (informational coding guidance)HCPCS

J7183	Injection, antihemophilic factor, per FVIII IU (Alphanate) — description present in policy
J7186	Injection, antihemophilic FVIII–von Willebrand factor complex (human), per FVIII IU (Humate-P) — description present in policy
J7187	Injection, antihemophilic factor (unspecified) — code referenced
J7179	Injection, von Willebrand factor (recombinant) (Vonvendi), per 1 IU vWF:RCo — description present in policy

Provider Requirements and Billing Rules

Prior Authorization

Prior authorization required

Obtain prior authorization before dispensing Alphanate, Humate-P, Wilate, or Vonvendi and submit supporting clinical documentation (office chart notes, laboratory results, current weight, and bleed history) demonstrating that the member meets all applicable initial or continued therapy criteria.

J7183
J7186
J7187
J7179

Prior Authorization

Hematologist involvement required

For initial approvals, the prescription must be written by or in consultation with a hematologist; include documentation of that involvement with the authorization request.

Clinical and Product Context

This policy covers plasma‑derived factor VIII–von Willebrand factor complexes (Alphanate, Humate‑P, Wilate) and the recombinant von Willebrand factor product Vonvendi for the treatment and prevention of bleeding in patients with Hemophilia A and von Willebrand disease (VWD). The products are FDA‑approved for control and prevention of bleeding episodes, perioperative management (product‑specific), on‑demand treatment, and select routine prophylaxis indications (for example, Wilate prophylaxis in patients ≥ 6 years and Vonvendi prophylaxis for certain severe type 3 VWD patients).

Dosing and administration are weight‑based and follow the FDA‑approved prescribing information for each product. Typical IV dosing categories include minor, moderate, and major bleeding episodes, as well as perioperative regimens and routine prophylaxis schedules. For example, Alphanate dosing is described by episode severity (minor 15 IU/kg every 12 hours; moderate 25 IU/kg every 12 hours; major 40–50 IU/kg loading then 25 IU/kg every 12 hours) with a maximum of 100 IU/kg/daymaximum up to 240 IU/kg/day; Wilate hemophilia major episodes 35–50 IU/kg with a maximum of 150 IU/kg/day, and Wilate VWD maximums of 60 IU/kg/day for VWD indications).

Vonvendi dosing likewise includes episode‑based regimens (minor 40–50 IU/kg loading followed by 40–50 IU/kg every 8–24 hours; major 50–80 IU/kg loading then 40–60 IU/kg every 8–24 hours) with product‑specific perioperative schedules and prophylaxis initiation of 40–60 IU/kg IV twice weekly for eligible patients and a prophylaxis maximum of 60 IU/kg twice weekly.

Providers must document the member’s current body weight (kilograms) to calculate dose; the policy added weight documentation as a required element in 1Q 2021 and clarifications in later reviews note weight is specifically required for initial dosing and when requesting dose increases. The policy requires that administered doses do not exceed the FDA‑approved maximum recommended dose for the relevant indication. Definitions and examples of serious spontaneous bleeds (intracranial, neck/throat, gastrointestinal, joints, deep muscle compartments, or mucous membranes) are provided in Appendix D to support indications such as routine prophylaxis eligibility and perioperative use.

Numeric Thresholds and Defined Terms

Thresholds and Dose Constraints

Severe hemophilia definitionFVIII activity level < 1%

Desmopressin trial thresholdApplies when FVIII coagulant activity levels ≤ 5% and age ≥ 2 years (trial of DDAVP required unless contraindicated)

Alphanate maximum dose constraint (example)Maximum dose = 100 IU/kg/day (FDA prescribing information)

Humate-P maximum dose constraint (example)Maximum dose = up to 240 IU/kg/day (per prescribing information)

Wilate maximum dose constraints (examples)Hemophilia maximum = 150 IU/kg/day; VWD maximum = 60 IU/kg/day; routine prophylaxis max = 40 IU/kg/day (per prescribing information)

Vonvendi prophylaxis maximum constraint (example)Prophylaxis dosing maximum = 60 IU/kg twice weekly (initiation 40–60 IU/kg twice weekly) and minor surgery max 60 IU/kg/day (per prescribing information)

Policy Updates and Material Changes

2025-02-25annual review / revised criteriaLatest

1Q 2025 annual review: revised the desmopressin (DDAVP) trial requirement to apply only for age ≥ 2 years; updated authorization durations — Medicaid/HIM prophylaxis set to 6 months (12 months for HIM Texas) and continued prophylaxis to 12 months, Commercial prophylaxis set to 6 months or to the member's renewal date; references reviewed and updated.

2024-05-24continued therapy clarification

Clarified that for continued therapy, current body weight is required only if requesting a higher dose than previously approved.

2024-02-24

Policy Summary

PayerCentene

PolicyFactor VIII–von Willebrand Factor Complex and von Willebrand Factor products (Alphanate, Humate-P, Wilate, Vonvendi)

Policy CodePolicy CP PHAR.216

Change TypeAnnual revisions and clarifications (2021–2025)

Effective DateMay 1, 2016

Next Review Date

SourceLink

On This Page

Treatment of bleeding episodes (Humate-P, Vonvendi, Wilate as specified).
Perioperative management (product-specific: Alphanate, Humate-P, Wilate, Vonvendi depending on product).
Routine prophylaxis to reduce frequency of bleeding episodes when product-specific criteria met (e.g., Vonvendi for severe type 3 VWD receiving on-demand therapy; Wilate for age ≥ 6 years).

Documentation of member's current body weight (kg).

Dose does not exceed the FDA-approved maximum recommended dose for the relevant indication.

Documentation Required

Weight documentation for dosing

Document the member's current body weight in kilograms for initial and continued therapy; current weight is specifically required when requesting a higher dose than previously approved.

Documentation Required

Desmopressin (DDAVP) trial documentation

For applicable patients age ≥ 2 years (VWD type 1 or 2 except 2B, or when FVIII activity thresholds apply), document a trial and failure of desmopressin acetate (DDAVP) unless contraindicated, clinically significant adverse effects occur, or an appropriate formulation is unavailable.

Applies when FVIII coagulant activity levels ≤ 5% and age ≥ 2 years per thresholds

Denial Risk

Non‑FDA use or insufficient documentation may be denied

Requests for non‑FDA‑approved indications that lack sufficient off‑label documentation per the referenced off‑label policies (CP.CPA.09, HIM.PA.154, CP.PMN.53) may be denied.

Refer to CP.CPA.09 (Commercial), HIM.PA.154 (HIM), or CP.PMN.53 (Medicaid) for off‑label documentation requirements

Definitions

Serious spontaneous bleedA bleeding episode without apparent cause occurring in sites including intracranial; neck/throat; gastrointestinal; joints (hemarthrosis); muscles (especially deep compartments such as the iliopsoas, calf, forearm); or mucous membranes of the mouth, nose, and genitourinary tract.

DDAVP (Desmopressin acetate)Desmopressin acetate (Stimate nasal spray; generic injection solution) — trial required for certain VWD or FVIII activity thresholds unless contraindicated; dosing examples: injection 0.3 mcg/kg IV every 48 hours; nasal spray dosing per product labeling.

AbbreviationsDDAVP = desmopressin acetate; FVIII = factor VIII; VWD = von Willebrand disease.

No coverage criteria policy (Medicaid) — relationship: read_with

annual review / appendix update

1Q 2024 annual review: updated sites of serious bleeds in Appendix D per WFH guideline and reviewed/updated references.

2023-08-25authorization duration update

Extended initial and continued authorization durations for prophylaxis to 12 months for HIM Texas (update applied during 1Q 2023 activities).

2023-02-23annual review / criterion clarification

1Q 2023 annual review: removed the term 'life-threatening' from the 'life‑threatening or serious bleed' criterion to avoid potential misinterpretation; references reviewed and updated.

2022-05-22clarification / new indication

1Q 2022: clarified that FVIII activity level and bleed history documentation requirement for Wilate routine prophylaxis applies only to new starts; added newly approved indication for Vonvendi routine prophylaxis.

2021-02-21annual review / documentation requirement

1Q 2021 annual review: added requirement for documentation of member's body weight for dosing calculations and added a trial of desmopressin for applicable VWD patients (type 1 or 2 except 2B).